Sunovion Pharmaceuticals Inc.

Sepracor, Inc.

Judy Caron

Thomas Wessel

Karim Lalji

Timothy J Barberich

Roger P Bakale

H Scott Wilkinson

Zhengxu Han

Mark A Varney

Surendra Singh

Stefan G Koenig

Xiping Su

Surendra P Singh

Stephan G Koenig

One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

Process for preparation of trans 4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-1Napthalenamine

The invention relates to the use of eszopiclone for the treatment of low-level, chronic pain and fatigue associated with pain.

Methods of treatment of chronic pain using eszopiclone

One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and/or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HTmodulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound; and a SRI, NRI, 5-HTmodulator or DRI.

Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression

The invention relates to the use of eszopiclone for the treatment of symptoms accompanying perimenopause or menopause.

Methods of treatment of menopause and perimenopause using eszopiclone

Growing community of inventors

Westwood, MA, United States of America

Judy Caron